CD24 and breast carcinoma: Using immunohistochemistry and immunofluorescence, we examined the CSC properties of LCTCs and BCTCs using the accepted breast cancer stem markers CD29, CD44, and CD24 (Al‐Hajj et al., 2003; Karsten and Goletz, 2013; Ouhtit et al., 2007; Shackleton et al., 2006).